惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

Last Week in AI
Last Week in AI
GbyAI
GbyAI
Apple Machine Learning Research
Apple Machine Learning Research
奇客Solidot–传递最新科技情报
奇客Solidot–传递最新科技情报
N
Netflix TechBlog - Medium
量子位
aimingoo的专栏
aimingoo的专栏
D
Docker
F
Fortinet All Blogs
T
Tailwind CSS Blog
V
V2EX
D
DataBreaches.Net
Google DeepMind News
Google DeepMind News
MyScale Blog
MyScale Blog
G
Google Developers Blog
罗磊的独立博客
MongoDB | Blog
MongoDB | Blog
Microsoft Security Blog
Microsoft Security Blog
Microsoft Azure Blog
Microsoft Azure Blog
WordPress大学
WordPress大学
博客园 - 三生石上(FineUI控件)
小众软件
小众软件
A
About on SuperTechFans
IT之家
IT之家

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
argenx SE (ARGX) Discusses R&D Spotlight on Advancing FcR...
SA Transcripts · 2026-06-24 · via All Articles on Seeking Alpha

argenx SE (ARGX) Discusses R&D Spotlight on Advancing FcRn Leadership in Autoimmune Myositis June 23, 2026 2:00 PM EDT

Company Participants

Beth DelGiacco
Karen Massey - CEO & Executive Director
Leentje De Ceuninck
Luc Truyen - Chief Medical Officer
Joshua Bryson
Sandrine Piret-Gerard - Chief Commercialization Officer
Peter Ulrichts - Chief Scientific Officer
An Vandebosch - Head of Development

Conference Call Participants

Arjun Seth
Avery LaChance
Rohit Aggarwal
Yatin Suneja - Guggenheim Securities, LLC, Research Division
Andy Chen - Wolfe Research, LLC
Alexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research Division
Tazeen Ahmad - BofA Securities, Research Division
David Nierengarten - Wedbush Securities Inc., Research Division
Samantha Semenkow - Citigroup Inc., Research Division
Shuting Cai - TD Cowen, Research Division
Xian Deng - UBS Investment Bank, Research Division
Danielle Brill Bongero - Truist Securities, Inc., Research Division
Sophia Graeff Buhl Nielsen - JPMorgan Chase & Co, Research Division
Jiayi Yuan - RBC Capital Markets, Research Division
Akash Tewari - Jefferies LLC, Research Division
Rajan Sharma - Goldman Sachs Group, Inc., Research Division

Presentation

Operator

Please welcome Beth DelGiacco.

Beth DelGiacco

Hi, and welcome to our Boston Innovation Hub. It's looking very transformed today. And welcome to our second R&D Spotlight event. Today, we're going to focus on autoimmune myositis and the opportunity for VYVGART to have a meaningful impact on patients' lives. We have a full house today. We have many investors and analysts. We also have our argenx colleagues here. And during that mix and mingle, we encourage you to get to know each other. We also have a lot of people joining on the webcast. So a big welcome to them as well.

Autoimmune myositis. We've actually transitioned from calling this disease or what is really a group of different diseases away from idiopathic inflammatory myopathies because idiopathic means of unknown origin. And the reality is, today, we know what drives myositis, which is our immune system. And so you're going to